Sangamo Therapeutics has entered a global licensing agreement with Genentech to advance the development of intravenous genomic medicines targeting neurodegenerative disorders.
According to the agreement, Genentech willpay Sangamo USD 50 million in upfront license fees and near-term milestone payments. Additionally, Sangamo could receive up to USD 1.9 billion upon achieving development and commercial milestones, as well as tiered royalties based on net sales of the products.
Through this partnership, Sangamo will grant Genentech exclusive licenses to its zinc finger repressors which target the Alzheimer's-related tau gene and another undisclosed neurological target, alongside Sangamo's proprietary AAV capsid, STAC-BBB, recognized for its effective blood-brain barrier penetration. Sangamo will manage transfer and preclinical tasks, whereas Genentech will lead clinical development, regulatory affairs, manufacturing, and commercialization.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.